Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | RECQL | P46063 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.54 |
| ▸ | TUBB | P07437 | 1/20 | 0.54 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.54 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.54 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6716706 | 0.84 | RXFP1 (0.51) | MAPK1SMN1; SMN2RXFP1KMT2ATSHR | |
| SCHEMBL6718796 | 0.84 | RAB9A (0.55) | MAPK1SMN1; SMN2RXFP1KMT2ATSHR | |
| SCHEMBL15528812 | 0.82 | MAPK1 (0.71) | MAPK1SMN1; SMN2KMT2ATSHRRECQL | |
| SCHEMBL8589705 | 0.81 | RAB9A (0.50) | MAPK1SMN1; SMN2RXFP1KMT2ATSHR | |
| SCHEMBL31087262 | 0.81 | MAPK1 (0.74) | MAPK1SMN1; SMN2RXFP1KMT2ATSHR | |
| SCHEMBL28634421 | 0.79 | SMN1; SMN2 (0.66) | MAPK1SMN1; SMN2RXFP1KMT2ATSHR | |
| SCHEMBL15528700 | 0.78 | MAPK1 (1.00) | MAPK1KMT2ATSHRRECQLKDM4E | |
| SCHEMBL6633552 | 0.77 | SMN1; SMN2 (1.00) | MAPK1SMN1; SMN2KMT2ATSHRRECQL | |
| SCHEMBL30587183 | 0.77 | SMN1; SMN2 (1.00) | MAPK1SMN1; SMN2KMT2ATSHRRECQL | |
| SCHEMBL15528615 | 0.76 | RXFP1 (1.00) | RXFP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087491-A1 | Electrophilic ketones for the treatment of herpesvirus infections | FLYNN DANIEL L (US) | 2004-05-06 | — | — | US | claimed |
| US-20030119721-A1 | Electrophilic ketones for the treatment of herpesvirus infections | G. D. SEARLE & CO., CORPORATE PATENT DEPARTMENT | 2003-06-26 | — | — | US | claimed |
| EP-0888322-B1 | ELECTROPHILIC KETONES FOR THE TREATMENT OF HERPESVIRUS INFECTIONS | SEARLE & CO (US) | 2002-09-18 | — | — | EP | claimed |
| EP-0888322-A2 | ELECTROPHILIC KETONES FOR THE TREATMENT OF HERPESVIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 1999-01-07 | — | — | EP | claimed |
| WO-1997034566-A2 | ELECTROPHILIC KETONES FOR THE TREATMENT OF HERPESVIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 1997-09-25 | — | — | WO | claimed |
| US-20040087491-A1 | Electrophilic ketones for the treatment of herpesvirus infections | FLYNN DANIEL L (US) | 2004-05-06 | — | — | US | disclosed |
| US-6673788-B2 | CONTAINING 2,2,2-TRIFLUORO-1-OXOETHYL GROUPS | G. D. SEARLE & CO. | 2004-01-06 | — | — | US | disclosed |
| US-6673784-B1 | HALOSUBSTITUTED ACETOPHENONES AS SELECTIVE HERPESVIRUS PROTEASE INHIBITORS | G. D. SEARLE & CO. | 2004-01-06 | — | — | US | disclosed |
| US-20030119721-A1 | Electrophilic ketones for the treatment of herpesvirus infections | G. D. SEARLE & CO., CORPORATE PATENT DEPARTMENT | 2003-06-26 | — | — | US | disclosed |
| EP-0888322-B1 | ELECTROPHILIC KETONES FOR THE TREATMENT OF HERPESVIRUS INFECTIONS | SEARLE & CO (US) | 2002-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087491-A1 | Electrophilic ketones for the treatment of herpesvirus infections | KHK, HCK, PBK | MAPK1 1447/4885SMN1; SMN2 3054/4885RXFP1 3931/4885 |
| US-20030119721-A1 | Electrophilic ketones for the treatment of herpesvirus infections | KHK, HCK, PBK | MAPK1 1447/4885SMN1; SMN2 3054/4885RXFP1 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.